Natera has announced findings from a study evaluating its personalised tumour-informed molecular residual disease (MRD) test, Signatera, in individuals with soft tissue and bone sarcomas.

Fürstenau M, Robrecht S, Schneider C, et al. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial. Blood . 2025;145(12):1282 ...